Drug Type Small molecule drug |
Synonyms Articaine Hydrochloride and Epinephrine Tartrate, Compound Articaine Hydrochloride, 复方盐酸阿替卡因 + [8] |
Mechanism ADRA1 agonists(Adrenergic receptor alpha-1 agonists), SCNA modulators(Sodium channel alpha subunit modulators), β-adrenoceptors agonists(Beta adrenergic receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date DE (01 Jan 1976), |
Regulation- |
Molecular FormulaC13H21ClN2O3S |
InChIKeyGDWDBGSWGNEMGJ-UHFFFAOYSA-N |
CAS Registry23964-57-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anesthesia | DE | 01 Jan 1976 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammatory pain | Preclinical | US | - | - |
Not Applicable | - | 4% articaine with epinephrine 1:100,000 | seiomiuahm(ihjnjevxbo) = IANB with 4% articaine and epinephrine 1:100,000 did not have any significant change in PBF for the first 20 min post injection in mandibular first molars, and for 45 min post injection in the canines. However, a hyperemic response occurred during 25-60 min post injection in the molars, and between 60 and 75 min post injection in the canines. Thereafter, the PBF in both teeth returned to the baseline. qtuehdjyqs (udwwytelwk ) | - | 01 Jan 2021 |